AR and neoplasm: In addition to the inherent resistance of the PSA−/low AR−/low cell subset to chemotherapy drugs and androgen signaling inhibitors, drug treatment inhibits AR signaling, thereby resulting in the acquisition of a PCSC phenotype by tumor cells [77].